Marilyn Tan is an Endocrinology/Metabolic physician affiliated with Stanford University. OpenAlex indexes 40 publications with 2,783 citations (h-index 13); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Stanford, CA 943052200
Telephone
650-723-4000Provider last certified this registry record 17 Apr 2024.
Clinical trials
- Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia
Sponsor: Dr. Tracey McLaughlin, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year202514 payments
- Novo Nordisk IncProgram year20251 payment
- Dexcom, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
73.8%GLP-1 receptor agonist27.5%Trulicity36%Mounjaro35%Ozempic23%Rybelsus6%Part D<11 patientsInsulin Analog15.9%Humalog Kwikpen U-10018%Lantus Solostar16%Novolog Flexpen11%Basaglar Kwikpen U-10010%Insulin Aspart Flexpen9%Tresiba Flextouch U-2007%Insulin Lispro Kwikpen U-1007%Fiasp Flextouch6%Tresiba Flextouch U-1006%Humalog Kwikpen U-2006%Insulin Glargine-Yfgn5%Part D<11 patients+ 7 more classes in this area
Hormonal (systemic)
21.2%l-Thyroxine19.4%Levothyroxine Sodium79%Synthroid14%Tirosint4%Thyquidity3%Part D<11 patientsThyroid Hormone Synthesis Inhibitor1.8%Methimazole100%Part D<11 patientsSensory organs
2.1%Corticosteroid2.1%Hydrocortisone100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Smartphone-based App to Assess Diabetic Peripheral Neuropathy
Journal of Diabetes Science and Technology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Renumathy Dhanasekaran, MD, PhD
Stanford University
Euan Ashley, MD
Stanford University
Sarah Donaldson, MD
Stanford University
Peter Fitzgerald, MD
Stanford University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”